focus -WSS

focus

author：knowledge 2025-09-30 01:12:37 - browse：8

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Steward Health Care files for bankruptcy

focus

WSS

How generative AI ratchets up security threats for health systems

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Use wet bulb globe temperature, not heat index, to protect workers

Bernie Sanders is gearing up to subpoena pharma CEOs

Wegovy leads to weight loss. Can it treat depression, too?

Sanofi strikes deal with Novavax, boosting the vaccine maker

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The cancer drug shortage isn’t new — and neither are the solutions

Wegovy leads to weight loss. Can it treat depression, too?

Apple is now the first public company to be valued at $3 trillion

Philips to halt sales of sleep apnea machines in U.S.

The cancer drug shortage isn’t new — and neither are the solutions

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Apple is now the first public company to be valued at $3 trillion

Sanofi strikes deal with Novavax, boosting the vaccine maker

The cancer drug shortage isn’t new — and neither are the solutions

New clues to why women have higher risk of autoimmune disorders

leisure time

CDC wastewater surveillance dashboard to track bird flu hotspots

Medicare drug price negotiation legal challenge met with skepticism

New clues to why women have higher risk of autoimmune disorders

Elevance, private equity launch primary care company

Dairy farmers resist CDC push for PPE against bird flu virus

Brain worms: The science behind RFK Jr.'s parasitic infection

focus

focus

focus

explore